Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium quadruplex viable tablets
- Development stage
- Unknown
- Lead developer
- Hangzhou Grand Biologic Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium quadruplex viable tablets, marketed under the brand name Silankang, is a live biotherapeutic product containing four distinct bacterial strains: *Bifidobacterium infantis*, *Lactobacillus acidophilus*, *Enterococcus faecalis*, and *Bacillus cereus*. It is primarily used to treat intestinal dysbiosis-related conditions such as diarrhea, constipation, and abdominal distension. The formulation works by replenishing beneficial gut flora, inhibiting the growth of pathogenic bacteria, and restoring the ecological balance of the intestinal microbiota. In clinical trials, it has been evaluated for the treatment of functional constipation, including specifically in pregnant women, to improve bowel movement frequency and stool consistency without systemic absorption.
- Brand names
- Silankang
- Other names
- 双歧杆菌四联活菌片Bifidobacterium infantis, Lactobacillus acidophilus, Enterococcus faecalis, and Bacillus cereus tabletsBifidobacterium Tetravaccine (Live), Oral
Beyond the preview
Go deeper on Bifidobacterium quadruplex viable tablets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium quadruplex viable tablets.